Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this Phase 2 study is to evaluate how the body handles the drug and the drug's effect on the body of participants with mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or mild AD who test positive for amyloid plaque.
| Condition | Intervention | Phase |
|---|---|---|
|
Alzheimer's Disease |
Drug: LY2886721 Drug: Placebo |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Pharmacokinetics/Dynamics Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Basic Science |
| Official Title: | Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease |
- Change from baseline to 12 weeks in cerebrospinal fluid (CSF) amyloid beta (Aβ)1-40 and Aβ1-42 concentrations [ Time Frame: Baseline, 12 weeks ] [ Designated as safety issue: No ]
- Change from baseline to 26 weeks in cerebrospinal fluid (CSF) amyloid beta (Aβ)1-40 and Aβ1-42 concentrations [ Time Frame: Baseline, 26 weeks ] [ Designated as safety issue: No ]
- Change from baseline in plasma amyloid beta (Aβ)1-40 and Aβ1-42 concentrations [ Time Frame: Baseline, 12 weeks, 26 weeks ] [ Designated as safety issue: No ]
- Change from baseline to 26 weeks in Neuropsychological Test Battery (NTB) [ Time Frame: Baseline, 26 weeks ] [ Designated as safety issue: No ]
- Change from baseline to 26 weeks in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) [ Time Frame: Baseline, 26 weeks ] [ Designated as safety issue: No ]
- Change from baseline to 26 weeks in the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) [ Time Frame: Baseline, 26 weeks ] [ Designated as safety issue: No ]
- Change from baseline to 26 weeks in Mini Mental State Examination (MMSE) [ Time Frame: Baseline, 26 weeks ] [ Designated as safety issue: No ]
- Change from baseline in cerebrospinal fluid (CSF) tau and phosphorylated tau (ptau) 181 concentrations [ Time Frame: Baseline, 12 weeks, 26 weeks ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 128 |
| Study Start Date: | March 2012 |
| Estimated Study Completion Date: | February 2014 |
| Estimated Primary Completion Date: | February 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 15 mg LY2886721
15 mg capsules orally once daily for 26 weeks. This dose will not be administered to new subjects once the site has approval for the protocol amendment.
|
Drug: LY2886721
One capsule administered orally once daily
|
|
Experimental: 35 mg LY2886721
35 mg capsules orally once daily for 26 weeks
|
Drug: LY2886721
One capsule administered orally once daily
|
|
Placebo Comparator: Placebo
1 placebo capsule orally once daily for 26 weeks
|
Drug: Placebo
One capsule administered orally once daily
|
|
Experimental: 70 mg LY2886721
70 mg capsules orally once daily for 26 weeks
|
Drug: LY2886721
One capsule administered orally once daily
|
Eligibility| Ages Eligible for Study: | 55 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Meets criteria for MCI due to AD or Mild AD
All participants will be required to undergo assessment via the Mini Mental State Examination (MMSE) scale at screening
Participants with MMSE scores of 20 to 26, inclusive, may be enrolled provided they meet the criteria for mild AD, as follows:
- Participant meets the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria for probable AD;
- Clinical Dementia Rating Scale (CDR) score of 0.5 or 1
- Positive scan for the presence of amyloid beta
Participants with MMSE of 27 to 30, inclusive, may be enrolled as participants with MCI due to AD provided they meet the following criteria:
- Gradual and progressive change in memory function as reported by the participant or a caregiver during a period of more than 6 months;
- Free and Cued Selective Reminding Test with Immediate Recall (FCSRT-IR): free recall ≤22 and total recall ≤46;
- Absence of dementia;
- Preservation of functional independence;
- Exclusion of other potential (vascular, traumatic, or medical) causes of cognitive decline, where possible;
- Positive scan for the presence of amyloid beta
- Women must be postmenopausal
- Men are required to use an approved barrier method of contraception if their partners are pregnant, or of childbearing potential and not using approved contraceptive methods
Exclusion Criteria:
- Participant in another drug or device study
- Have a history of frontotemporal dementia, Lewy body disease, vascular dementia, Huntington's disease or Parkinson's disease, progressive supranuclear palsy (PSNP) or other movement disorder
- Participants are not on a stable standard of care (acetylcholinesterase inhibitors, memantine) initiated less than two months prior to entry or have less than 4 weeks of stable therapy. Note: Stable standard of care is allowed
- Have had a serious infectious disease affecting the brain in the past 5 years
- Have had a serious or repeat head injury
- Have significant retinal impairment or disease
- Have had a stroke or other circulation problems that are affecting your current health
- Have had a seizure
- Have major depressive disorder and are not on a stable dose of medication. Participants who no longer meet the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision (DSM-IV) criteria for major depression may be included
- History of schizophrenia, bipolar disorder or severe mental illness.
- History of alcohol or drug abuse
- Have asthma, chronic obstructive pulmonary disease (COPD) or other breathing disease that is not controlled with medicine
- Have human immunodeficiency virus (HIV) or syphilis
- Are taking blood thinners
Contacts and Locations| Contact: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or | 1-317-615-4559 |
Show 34 Study Locations| Study Director: | Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) | Eli Lilly and Company |
More Information
No publications provided
| Responsible Party: | Eli Lilly and Company |
| ClinicalTrials.gov Identifier: | NCT01561430 History of Changes |
| Other Study ID Numbers: | 13735, I4O-MC-BACC, 2011-005217-37 |
| Study First Received: | March 21, 2012 |
| Last Updated: | May 1, 2013 |
| Health Authority: | United States: Food and Drug Administration Japan: Pharmaceuticals and Medical Devices Agency Italy: Ethics Committee Spain: Agencia Española de Medicamentos y Productos Sanitarios Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
Keywords provided by Eli Lilly and Company:
|
beta-secretase inhibitor |
Additional relevant MeSH terms:
|
Alzheimer Disease Cognition Disorders Dementia Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Tauopathies Neurodegenerative Diseases Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders |
ClinicalTrials.gov processed this record on May 22, 2013